BlackRock Amends MACROGENICS Stake, Maintains Passive Position
Ticker: MGNX · Form: SC 13G/A · Filed: 2024-01-24T00:00:00.000Z
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investing
TL;DR
**BlackRock still owns a big chunk of MACROGENICS, signaling stability.**
AI Summary
BlackRock, Inc. filed an amended Schedule 13G/A on January 24, 2024, disclosing its ownership in MACROGENICS INC as of December 31, 2023. This amendment, the 9th for this holding, indicates that BlackRock continues to hold a significant passive stake in the pharmaceutical company. For investors, this filing confirms that a major institutional investor like BlackRock maintains its position, which can be seen as a vote of confidence in MACROGENICS INC's long-term prospects, potentially influencing other investors' decisions.
Why It Matters
This filing shows BlackRock, a major institutional investor, still holds a significant stake in MACROGENICS INC, signaling continued confidence in the company's future.
Risk Assessment
Risk Level: low — This filing is a routine update from a passive institutional investor and does not indicate any immediate new risks or significant changes in strategy.
Analyst Insight
An investor should note that BlackRock's continued passive stake suggests stability, but this filing alone doesn't provide new information for a buy/sell decision. It's a routine update, not a change in investment thesis.
Key Players & Entities
- BlackRock, Inc. (company) — the reporting person and institutional investor
- MACROGENICS INC (company) — the subject company in which BlackRock holds shares
- December 31, 2023 (date) — the date of the event requiring this filing
- January 24, 2024 (date) — the filing date of the SC 13G/A
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, specifically Amendment No. 9, as stated in the filing.
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., as clearly identified in the 'Names of reporting persons' section of the filing.
What is the subject company of this filing?
The subject company is MACROGENICS INC, as indicated in the 'Name of Issuer' section of the Schedule 13G.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was December 31, 2023, as specified in the filing.
Under which rule was this Schedule 13G/A filed?
This Schedule 13G/A was filed under Rule 13d-1(b), as indicated by the 'X' in the appropriate box on the cover page.
From the Filing
EDGAR Filing Documents for 0001086364-24-002365 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home Company Search Current Page Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] SEC Accession No. 0001086364-24-002365 Filing Date 2024-01-24 Accepted 2024-01-24 14:27:19 Documents 1 Document Format Files Seq Description Document Type Size 1 us5560991094_012424.txt SC 13G/A 11645 Complete submission text file 0001086364-24-002365.txt 13433 Mailing Address 9704 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 Business Address 9704 MEDICAL CENTER DRIVE Rockville MD 20850 301-251-5172 MACROGENICS INC (Subject) CIK : 0001125345 (see all company filings) EIN. : 000000000 | State of Incorp.: DE | Fiscal Year End: 1231 Type: SC 13G/A | Act: 34 | File No.: 005-87928 | Film No.: 24555929 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences) Mailing Address 50 HUDSON YARDS NEW YORK NY 10001 Business Address 50 HUDSON YARDS NEW YORK NY 10001 212-810-5300 BlackRock Inc. (Filed by) CIK : 0001364742 (see all company filings) EIN. : 320174431 | State of Incorp.: DE | Fiscal Year End: 1231 Type: SC 13G/A SIC : 6211 Security Brokers, Dealers & Flotation Companies (CF Office: 02 Finance)